Martina Turroja
A5015475458- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Animal Virus Infections Studies
- Long-Term Effects of COVID-19
- Viral gastroenteritis research and epidemiology
- T-cell and B-cell Immunology
- Viral Infections and Immunology Research
- COVID-19 epidemiological studies
- Immune Cell Function and Interaction
- Bacillus and Francisella bacterial research
- SARS-CoV-2 detection and testing
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
Rockefeller University
2020-2023
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 deaths to date. Infection associated with the development of variable levels antibodies neutralizing activity, which can protect against infection in animal models1,2. Antibody decrease time, but, our knowledge, nature quality memory B cells that would be required produce upon reinfection not been examined. Here we report on humoral response a cohort 87 assessed at...
Here we report on the antibody and memory B cell responses of a cohort 20 volunteers who received Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-21-4. Eight weeks after second injection vaccine, showed high levels IgM IgG anti-SARS-CoV-2 spike protein (S) receptor-binding-domain (RBD) binding titre. Moreover, plasma neutralizing activity relative numbers RBD-specific cells vaccinated were equivalent to those individuals had recovered from natural infection5,6....
Abstract More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) remains difficult to control despite availability of several working vaccines. Progress in controlling is slowed emergence variants that appear be more transmissible and resistant antibodies 1,2 . Here we report on a cohort 63 individuals who have recovered from COVID-19 assessed at 1.3, 6.2 12 months SARS-CoV-2 infection, 41% whom also...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During time, memory cells express increasingly broad and potent antibodies are resistant mutations found in variants of concern 1 . As result, vaccination disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines high levels plasma neutralizing activity against all tested 1,2 Here we examine evolution five months...
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent individuals
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 deaths to date. Infection associated with development of variable levels antibodies neutralizing activity that can protect against infection in animal models. Antibody decrease time, but the nature quality memory B cells would be called upon produce re-infection not been examined. Here we report on humoral response a cohort 87 assessed at 1.3 6.2 months after...
To date severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 100 million individuals resulting in two deaths. Many vaccines are being deployed to prevent coronavirus disease 2019 (COVID-19) including novel mRNA-based 1,2 . These elicit neutralizing antibodies and appear be safe effective, but the precise nature of elicited is not known 3–6 Here we report on antibody memory B cell responses a cohort 20 volunteers who received either Moderna (mRNA-1273) or...
SARS-CoV-2 is responsible for an ongoing pandemic that has affected millions of individuals around the globe. To gain further understanding immune response in recovered individuals, we measured T cell responses paired samples obtained average 1.3 and 6.1 mo after infection from 41 individuals. The data indicate show persistent polyfunctional antigen–specific memory could contribute to rapid recall responses. Recovered also enduring alterations relative overall numbers CD4+ CD8+ cells,...
SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that contribute to better clinical outcomes. The receptor-binding domain (RBD) and the N-terminal (NTD) of spike trimer (S) constitute two major targets for antibodies. Here, we use NTD-specific probes capture anti-NTD memory B cells in a longitudinal cohort infected individuals, some whom were vaccinated. We found 6 complementation groups 58% targeted epitopes outside NTD supersite, neutralized either Gamma...
Abstract HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is effective but requires lifelong drug administration owing to stable reservoir of latent proviruses integrated into the genome CD4 + T cells 1 . Immunotherapy anti-HIV-1 antibodies has potential suppress and increase rate clearance infected 2,3 Here we report on clinical study in which people living HIV received seven doses combination two broadly neutralizing over 20 weeks presence or...
Abstract Feedback inhibition of humoral immunity by antibodies was first documented in 1909 1 . Subsequent studies showed that, depending on the context, can enhance or inhibit immune responses 2,3 However, little is known about how pre-existing influence development memory B cells. Here we examined cell response individuals who received two high-affinity anti-SARS-CoV-2 monoclonal and subsequently doses an mRNA vaccine 4–8 We found that recipients produced antigen-binding neutralizing...
Individuals who receive a third mRNA vaccine dose show enhanced protection against severe COVID-19, but little is known about the impact of breakthrough infections on memory responses. Here, we examine antibodies that develop after or fourth antigenic exposure by Delta Omicron BA.1 infection, respectively. A to antigen increases number B cells produce with comparable potency and breadth dose. infection increased variant-specific plasma antibody cell However, did not increase overall...
Abstract The omicron variant of SARS-CoV-2 infected very large numbers vaccinated and convalescent individuals 1–3 . penetrance this in the antigen experienced human population can be explained part by relatively low levels plasma neutralizing activity against Omicron people who were or with original Wuhan-Hu-1 strain 4–7 3 rd mRNA vaccine dose produces an initial increase circulating anti-Omicron antibodies, but titers remain 10-20-fold lower than are, many cases, insufficient to prevent...
Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains difficult to control despite availability of several excellent vaccines. Progress in controlling is slowed emergence variants that appear be more transmissible and resistant antibodies 1,2 . Here we report on a cohort 63 COVID-19-convalescent individuals assessed at 1.3, 6.2 12 months infection, 41% whom also received mRNA vaccines...
The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale pace. As result, current regimens comprise diverse vaccine modalities, immunogen combinations, dosing intervals. Here, we compare vaccine-specific antibody memory B cell responses following two-dose mRNA, single-dose Ad26.COV.2S, ChAdOx1, or combination ChAdOx1/mRNA vaccination. Plasma-neutralizing activity, as well magnitude, clonal composition, maturation...
Despite mRNA vaccination, elderly individuals remain especially vulnerable to severe consequences of SARS-CoV-2 infection. Here, we compare the memory B cell responses in a cohort and younger who received booster vaccinations. Plasma neutralizing potency breadth were similar between two groups. By contrast, absolute number SARS-CoV-2–specific cells was lower elderly. Antibody sequencing revealed that compartments more clonal less diverse. Notably, antibodies from preferentially targeted...
The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either the two available mRNA vaccines. In addition, has been less effective severe disease during Omicron surge. Here, we examined memory B cell response to vaccination. Compared with vaccines, recipients had significantly numbers RBD-specific cells 1.5 or 6 mo after Despite numbers, overall quality responses appears be similar,...
Abstract SARS-CoV-2 is responsible for an ongoing pandemic that affected millions of individuals around the globe. To gain further understanding immune response in recovered we measured T cell responses paired samples obtained average 1.3 and 6.1 months after infection from 41 individuals. The data indicate show persistent polyfunctional antigen specific memory could contribute to rapid recall responses. In addition, enduring alterations relative numbers CD4 + CD8 cells, expression...
Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year. During time, memory B cells express increasingly broad and potent antibodies are resistant mutations found in variants of concern 1 . As a result, vaccination disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines high levels plasma neutralizing activity against all tested 1, Here, we examine cell evolution 5...
Feedback inhibition of humoral immunity by antibodies was initially documented in guinea pigs Theobald Smith 1909, who showed that passive administration excess anti-Diphtheria toxin inhibited immune responses1. Subsequent work can enhance or inhibit responses depending on antibody isotype, affinity, the physical nature antigen, and engagement immunoglobulin (Fc) complement (C') receptors2,3. However, little is known about how pre-existing might influence subsequent development memory B...
SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that contribute to better clinical outcomes. The receptor binding domain (RBD) and the N-terminal (NTD) of spike trimer (S) constitute two major targets for system. Neutralizing antibodies targeting RBD bind several different sites on this domain. In contrast, most NTD characterized date a single supersite, however these were obtained by methods not specific. Here we use specific probes focus anti-NTD memory B cells...
The emergence of severe acute respiratory syndrome coronavirus 2 variants that have greater transmissibility and resistance to neutralizing antibodies has increased the incidence breakthrough infections. We show infection increases antibody titers varying degrees depending on nature variant number vaccine doses previously administered. Omicron resulted in were highest across all groups, particularly against Omicron.
Abstract Individuals that receive a 3 rd mRNA vaccine dose show enhanced protection against severe COVID19 but little is known about the impact of breakthrough infections on memory responses. Here, we examine antibodies develop after or 4 th antigenic exposure by Delta Omicron BA.1 infection, respectively. A to antigen increases number B cells produce with comparable potency and breadth dose. infection increased variant specific plasma antibody cell However, did not increase overall...